The operational team

The operational team coordinates evaluations, due diligence, negotiations, investment processes, exit planning, portfolio company support, communications and administration.

Sarah Fredriksson - CEO

PhD and M.Sc. from Lund University. CEO of P.U.L.S. AB. She has a background as founder and CEO of Genovis AB (listed on First North, Nasdaq OMX Nordic) and most recently CEO of Edvince AB. Currently board member of LU Holding and SwedenBio and other board member assignments in the life science sector as well as of Sparbankstiftelsen Skånes Riskkapitalstiftelse. Former board member of AcuCort AB.

Mats Ardevall - Vice President, CFO

M.Sc. Industrial Engineering and Management. He has since 1984 worked in the pharma and POC diagnostic industry in various positions within Finance, most recently as CFO/Director of Finance of HemoCue.


Björn Dellgren - Vice President, New Project Investments

M.Sc.(BA). Former Partner at BankInvest, Denmark and has worked with international biotech venture investments and fund management since 2000. Previous Director of Business Development at Pharmacia and various international positions in sales, marketing and business management at Pharmacia and the American pharmaceutical company, Lederle. Currently board member of Cernelle AB and previous board member of CMC Biologics, Denmark. Project leader of Adenovir Pharma AB.

Carina Eldh - Director, Finance & Administration

Financial and administrative support for PULS and its portfolio companies since 2011. Accountant with 20 years of experience in accounting, auditing and taxation matters. Previous positions at KPMG and other accounting firms, the Swedish Tax Agency and Öresundskraft.


Fredrik Lindgren - Vice President, Chief Business Officer

PhD, M.Sc. in chemistry from Umeå University. He has a background in the pharmaceutical industry with key positions in the area of business development processes at AstraZeneca and Umetrics AB among others. Most recently, he held the position Senior Director, Head of Global Business Development at LEO Pharma.

Jeanette Robertsson - Vice President, Chief Development Officer

PhD, M.Sc. in Pharmacy, followed by Post-doc at Georgetown University, Washington D.C. and University of Pittsburgh, Pittsburgh, Pennsylvania, resulting in 20 publications in peer-reviewed scientific journals. Has since 1991 worked within the pharma industry with international responsibility as Medical Director with close collaboration with regulatory affairs, international marketing and pre-clinical departments, as Project Manager of drug development projects, and as Director of Clinical Trial Management, with international overall responsibility of clinical trials, regulatory affairs and drug safety. She has held positions at Novartis, Perstorp Pharma, Searle Scandinavia, Tigran Technologies and CDC. Project leader of Laccure AB, Trophea AB and Belina Pharma AB. Board member of Glactone Pharma AB.